Pavion Blue Capital LLC Has $4.68 Million Stake in Johnson & Johnson (NYSE:JNJ)

Pavion Blue Capital LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 0.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 32,375 shares of the company’s stock after selling 126 shares during the period. Johnson & Johnson comprises 2.2% of Pavion Blue Capital LLC’s holdings, making the stock its 16th biggest position. Pavion Blue Capital LLC’s holdings in Johnson & Johnson were worth $4,682,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Howard Capital Management Inc. lifted its position in shares of Johnson & Johnson by 5.8% in the fourth quarter. Howard Capital Management Inc. now owns 18,879 shares of the company’s stock valued at $2,730,000 after buying an additional 1,029 shares during the last quarter. Integral Investment Advisors Inc. lifted its position in shares of Johnson & Johnson by 1.7% in the fourth quarter. Integral Investment Advisors Inc. now owns 16,822 shares of the company’s stock valued at $2,433,000 after buying an additional 288 shares during the last quarter. Tradewinds Capital Management LLC lifted its position in shares of Johnson & Johnson by 311.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 12,524 shares of the company’s stock valued at $1,811,000 after buying an additional 9,481 shares during the last quarter. Marshall Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $1,171,000. Finally, ST. Nicholas Private Asset Management Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $1,576,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Bank of America dropped their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Morgan Stanley dropped their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Barclays lifted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Trading Up 1.5 %

Shares of JNJ opened at $166.13 on Wednesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The business’s fifty day moving average is $149.72 and its 200-day moving average is $155.92. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $399.98 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.